We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Marinus (MRNS) Up 20% on Financial and Pipeline Updates
Read MoreHide Full Article
Marinus Pharmaceuticals (MRNS - Free Report) gains 20% on Sep 19, as the company highlights updates on its financial performance and pipeline progress focused on the development of therapies targeting major central nervous system disorders, during an Investor and Analyst Event in New York.
MRNS has been witnessing rapid adoption of its lead product, Ztalmy (ganaxolone), approved for treating seizures associated with CDKL5 deficiency disorder (CDD) in patients aged two years and older. For the third quarter of 2023, Marinus expects net product revenues in the range of $5-$5.2 million. The Zacks Consensus Estimate for product revenues is pegged at $6.54 million. The company remains on track to meet its full-year net product projection of $17-$18.5 million.
Ztalmy received approval in the United States in March 2022. In July 2023, it also gained approval in Europe for the adjunctive treatment of epileptic seizures associated with CDD in patients aged between two and 17 years. The drug is already generating incremental sales, exceeding management’s expectations. The company recorded sales of $7.58 million in the first half of 2023.
Shares of Marinus have rallied 76.6% year to date against the industry’s 4.6% decline.
Image Source: Zacks Investment Research
Looking ahead, the company expects its cash, cash equivalents, and short-term investments to be in the range of $170-$175 million at the end of the third quarter of 2023. This balance is expected to support MRNS’ operating expenses and capital expenditure requirements in the fourth quarter of 2024.
These projected balances will help Marinus to efficiently evaluate its two late-stage studies of ganaxolone for refractory status epilepticus (RSE) and tuberous sclerosis complex (TSC).
Status epilepticus is a severe neurological disease, and over 50% of patients are unresponsive to first or second-line therapies. The company is evaluating ganaxolone in a phase III RAISE study for RSE. The company has enrolled more than 70% patients in the study and expects to complete enrollment for an interim analysis by January 2024. The top-line data is expected in the first quarter of 2024 if the study meets the pre-defined stopping criteria from the interim analysis.
Furthermore, MRNS is evaluating ganaxolone in a phase III Trust TSC study for patients with TSC. Data from the study is expected by mid-2024.
In the past 90 days, the Zacks Consensus Estimate forAnika Therapeutics has narrowed from a loss of $1.41 per share to a loss of $1.24 for 2023. The bottom-line estimate has widened from a loss of 79 cents to a loss of 82 cents for 2024 during the same time frame. Shares of the company have lost 40.0% year to date.
ANIK’s earnings beat estimates in one of the trailing four quarters and missed the mark in the remaining three, delivering an average negative surprise of 32.12%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to a loss of $2.77 for 2024 during the same time frame. Shares of the company have lost 20.0% year to date.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.
In the past 90 days, the Zacks Consensus Estimate for Corcept’s earnings has gone up from 62 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 61 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 62.3% year to date.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Marinus (MRNS) Up 20% on Financial and Pipeline Updates
Marinus Pharmaceuticals (MRNS - Free Report) gains 20% on Sep 19, as the company highlights updates on its financial performance and pipeline progress focused on the development of therapies targeting major central nervous system disorders, during an Investor and Analyst Event in New York.
MRNS has been witnessing rapid adoption of its lead product, Ztalmy (ganaxolone), approved for treating seizures associated with CDKL5 deficiency disorder (CDD) in patients aged two years and older. For the third quarter of 2023, Marinus expects net product revenues in the range of $5-$5.2 million. The Zacks Consensus Estimate for product revenues is pegged at $6.54 million. The company remains on track to meet its full-year net product projection of $17-$18.5 million.
Ztalmy received approval in the United States in March 2022. In July 2023, it also gained approval in Europe for the adjunctive treatment of epileptic seizures associated with CDD in patients aged between two and 17 years. The drug is already generating incremental sales, exceeding management’s expectations. The company recorded sales of $7.58 million in the first half of 2023.
Shares of Marinus have rallied 76.6% year to date against the industry’s 4.6% decline.
Image Source: Zacks Investment Research
Looking ahead, the company expects its cash, cash equivalents, and short-term investments to be in the range of $170-$175 million at the end of the third quarter of 2023. This balance is expected to support MRNS’ operating expenses and capital expenditure requirements in the fourth quarter of 2024.
These projected balances will help Marinus to efficiently evaluate its two late-stage studies of ganaxolone for refractory status epilepticus (RSE) and tuberous sclerosis complex (TSC).
Status epilepticus is a severe neurological disease, and over 50% of patients are unresponsive to first or second-line therapies. The company is evaluating ganaxolone in a phase III RAISE study for RSE. The company has enrolled more than 70% patients in the study and expects to complete enrollment for an interim analysis by January 2024. The top-line data is expected in the first quarter of 2024 if the study meets the pre-defined stopping criteria from the interim analysis.
Furthermore, MRNS is evaluating ganaxolone in a phase III Trust TSC study for patients with TSC. Data from the study is expected by mid-2024.
Marinus Pharmaceuticals, Inc. Price and Consensus
Marinus Pharmaceuticals, Inc. price-consensus-chart | Marinus Pharmaceuticals, Inc. Quote
Zacks Rank & Other Stocks to Consider
Marinus currently carries a Zacks Rank #3 (Hold).
Some other top-ranked stocks in the same industry are Anika Therapeutics (ANIK - Free Report) , Annovis Bio (ANVS - Free Report) and Corcept Therapeutics (CORT - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate forAnika Therapeutics has narrowed from a loss of $1.41 per share to a loss of $1.24 for 2023. The bottom-line estimate has widened from a loss of 79 cents to a loss of 82 cents for 2024 during the same time frame. Shares of the company have lost 40.0% year to date.
ANIK’s earnings beat estimates in one of the trailing four quarters and missed the mark in the remaining three, delivering an average negative surprise of 32.12%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to a loss of $2.77 for 2024 during the same time frame. Shares of the company have lost 20.0% year to date.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.
In the past 90 days, the Zacks Consensus Estimate for Corcept’s earnings has gone up from 62 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 61 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 62.3% year to date.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.